RxDoctor Payments Data

Kathleen Lenz

Family · Boonville, MONPI 1801014360

Payments from drug & device makers

$510in general payments, 2019–2025

Across 22 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$180
  • AstraZeneca$69
  • Abbott$63
  • AbbVie$40
  • Boehringer Ingelheim$30
  • Otsuka America Pharmaceutical, Inc.$25
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510 in reported general payments places this provider in the 55th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$54,870
Medicare patients
236
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$92,156
OzempicSemaglutide39$48,738
EliquisApixaban41$40,651
JanuviaSitagliptin Phosphate29$35,774
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,678
JardianceEmpagliflozin21$26,267
FarxigaDapagliflozin Propanediol14$14,438
GemtesaVibegron19$11,465
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$10,905
Omeprazole372$6,848
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,324
ArexvyRsvpref3 Antigen/As01e/Pf19$5,342
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp16$5,219
Gabapentin185$4,417
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humulin 70-30$12$93,440100 claims
Novo NordiskOzempic$180$48,73839 claims
PfizerEliquis, Premarin$16$43,57754 claims
Boehringer IngelheimJardiance$30$26,26721 claims
AstraZenecaFarxiga$69$14,43814 claims
Sumitomo Pharma America, Inc.Gemtesa$16$11,46519 claims
AbbVieSynthroid$40$3,57950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,812 family providers in Missouri.

Other family in Boonville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →